AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$GALT

GALECTIN THERAPEUTICS INC

Price · $GALTvia TradingView
AI sentiment · 7d2 articles
AUG 2net (bullish − bearish)AUG 8
Bullish
1
Neutral
0
Bearish
1
Insider · 30dFeed →
Buys
—
0 txs
Sells
$83K
1 txs
Jamil Khurram1× · $83K
10b5-1 plan100%
Top stories · $GALTMore →
AUG 4·finanznachrichten.deMed

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

AUG 4·SEC EDGAR 8-K

GALECTIN THERAPEUTICS INC (GALT): Unregistered Sales of Equity Securities

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2026 GALECTIN THERAPEUTICS INC (Exact name of registra

JUL 14·rttnews.com

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.

GALT sentiment & insider activity

Over the past 7 days, alphai's AI scored 2 news stories mentioning GALT (GALECTIN THERAPEUTICS INC). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent GALT coverage spans corporate actions, market movers and financial news.

In the last 30 days, GALT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($83K). The most active reporter was Jamil Khurram, Chief Medical Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.

What's driving GALT

  • Debt elimination should reduce near-term balance-sheet stress and improve capitalization, but it also increases share count and can pressure near-term valuation.

    finanznachrichten.de · Aug 4, 2026

  • This is a dilutive conversion tied to a large related-party line of credit, with near-term overhang risk from potential resale registration.

    SEC EDGAR 8-K · Aug 4, 2026

  • FDA endpoint alignment reduces regulatory uncertainty and can improve probability-weighted outcomes for belapectin.

    rttnews.com · Jul 14, 2026

  • The deal is a platform-building step that could change GALT’s near-term revenue mix and execution risk in defense electronics.

    rfglobalnet.com · Jun 26, 2026

  • FDA alignment on Phase 3 design is a meaningful de-risking step that can improve odds for successful endpoints and timing.

    rttnews.com · Jun 24, 2026

alphai scores every news story that mentions GALT with an AI model for sentiment and relevance, and aggregates insider trades from GALECTIN THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GALT

Score
AUG 4$GALTMedAI 8/10finanznachrichten.de

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

4 min read
AUG 4$GALTMedSEC EDGAR 8-K

GALECTIN THERAPEUTICS INC (GALT): Unregistered Sales of Equity Securities

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2026 GALECTIN THERAPEUTICS INC (Exact name of registra

3 min read
JUL 14$QTTBMedAI 8/10rttnews.com

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.

7 min read
JUN 26$GALTMedrfglobalnet.com

Godspeed-Backed GALT Aerospace Announces Strategic Partnership With North Star Scientific

GALT Aerospace, backed by Godspeed Capital, said it acquired North Star Scientific Corporation (NSS), a Hawaii-based defense electronics maker. NSS designs high-power RF amplifiers, transmitters, antennas and electronically scanned arrays for C2, sensing and AEW&C, serving U.S. Air Force and Navy programs. GALT said the deal expands its C3ISR portfolio and program base; NSS is GALT’s first acquisition.

4 min read

Related tickers

More in Biotechnology